Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-GLA/alpha-Galactosidase A Antibody (5V259) is a Mouse antibody targeting GLA/alpha-Galactosidase A. Anti-GLA/alpha-Galactosidase A Antibody (5V259) can be used in ELISA,ELISA(Cap).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μL | $92 | 7-10 days | |
100 μL | $269 | 7-10 days |
Description | Anti-GLA/alpha-Galactosidase A Antibody (5V259) is a Mouse antibody targeting GLA/alpha-Galactosidase A. Anti-GLA/alpha-Galactosidase A Antibody (5V259) can be used in ELISA,ELISA(Cap). |
Alias | GLA/α-Galactosidase A Protein, galactosidase, α, galactosidase, alpha, Ags |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 5V259 |
Reactivity | Human |
Application | ELISA,ELISA(Cap) |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human alpha-Galactosidase A (rh alpha-Galactosidase A; TMPY-01727; NP_000160.1; Met1-Leu429). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction. |
Conjucates | Unconjugated |
Immunogen | Recombinant Human alpha-Galactosidase A Protein (TMPY-01727) |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.